The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of the multikinase inhibitor dovitinib (TKI258) or placebo in combination with fulvestrant in postmenopausal, endocrine resistant HER2-/HR+ breast cancer.
Fabrice Andre
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Richard Greil
No relevant relationships to disclose
Neelima Denduluri
No relevant relationships to disclose
Alejandro Javier Yovine
Employment or Leadership Position - Novartis
Cathy Reddick
Employment or Leadership Position - Novartis
Stock Ownership - Novartis (B)
Matthew Squires
Employment or Leadership Position - Novartis
Yong Zhang
Employment or Leadership Position - Novartis
Kimberly Blackwell
No relevant relationships to disclose